Market Overview:
The global clindamycin phosphate injection market is expected to register a CAGR of 5.5% during the forecast period, 2018-2030. The market growth can be attributed to the increasing incidence of hospital-acquired infections (HAIs), rising demand for injectable drugs, and growing number of clinical trials for clindamycin phosphate injection. Based on type, the global clindamycin phosphate injection market is segmented into 150mg/ml, 300mg/50ml, 600mg/50ml and 900mg/50ml. The 150mg/ml segment is expected to account for the largest share in terms of revenue in 2018 and is projected to grow at a CAGR of 5.8% during the forecast period. This can be attributed to its lower price point as compared to other types and wide availability across regions. Based on application, the global clindamycin phosphate injection market is segmented into hospitals, clinics and recovery centers. Hospitals are estimated to account for majority share in terms of revenue in 2018 owing high prevalence rate HAIs across different geographies coupled with rising demand from patients suffering from serious infections such as sepsis syndrome or pneumonia .
Product Definition:
Clindamycin phosphate injection is a drug used to treat serious infections caused by bacteria. It belongs to a class of antibiotics called lincosamides.
150mg/ml:
150 mg/ml is a concentration of clindamycin phosphate used for the treatment of bacterial vaginosis (BV), infections in the urinary tract, and bacterial pneumonia. It is also used as an antibiotic against non-specifically induced acute inflammation in patients with burns. Increasing prevalence of BV globally has led to high demand for 150 mg/ml clindamycin phosphate injection which further boosts market growth.
300mg/50ml:
300mg/50ml is a generic medicine used for the treatment of bacterial vaginosis (BV), as well as some other vaginal infections. It is one of the most common causes of vaginal odor and discharge.
300 mg Clindamycin phosphate topical gel, usually applied once a day, every day to 3 or 4 weeks depending on the severity and type of infection.
Application Insights:
The hospital application segment led the global market in 2017 and is projected to expand at a revenue-based CAGR of XX% over the forecast period. The rising number of hospital-acquired infections, especially among patients with weak immune systems, is expected to drive demand for clindamycin phosphate injections over the coming years.
The clinics application segment held a significant share of 23.4% in 2017 owing to high product penetration for treating skin infections caused by various bacteria including Staphylococcus aureus and Streptococcus pyogenes among others that require long-term treatment courses due to their resistant nature against commonly used oral antibiotics such as penicillin and methicillin.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of players and increased healthcare expenditure. Moreover, rising incidence of Clostridium difficile infections is expected to boost product demand. The U.S., which accounted for more than 75% share in North America market, is anticipated to be one of the lucrative markets for clindamycin phosphate due to its high rate of utilization coupled with favorable reimbursement scenario.
Asia Pacific region is projected to witness fastest growth over the forecast period owing to increasing healthcare spending by governments along with growing awareness about various treatment options available for infectious diseases such as Clostridium difficile infection (CDI). In addition, improving economic conditions are likely contribute toward faster growth during the forecast period from 2018-2030 in this region.
Growth Factors:
- Increasing incidence of infectious diseases: The increasing incidence of infectious diseases is one of the key growth drivers for the clindamycin phosphate injection market. Clindamycin phosphate is a widely used antibiotic for the treatment of various types of infections, including skin infections, respiratory tract infections, and intra-abdominal infections.
- Rising demand from emerging markets: The clindamycin phosphate injection market is witnessing high growth rates in emerging markets such as China and India due to the rising awareness about its benefits and increasing demand from hospitals and clinics in these regions.
- Technological advancements: The development of novel drug delivery technologies has helped to expand the applications scope for clindamycin phosphate injection, thereby driving its growth prospects further. For instance, Pfizer’s DYNAVAX TECHNOLOGIES Corporation has developed a needle-free injector system that uses compressed air to deliver drugs through the skin without a needle prick or pain associated with injections. This technology can be used to administer clindamycin phosphate injections effectively and safely without any pain or discomfort to patients.
Scope Of The Report
Report Attributes
Report Details
Report Title
Clindamycin Phosphate Injection Market Research Report
By Type
150mg/ml, 300mg/50ml, 600mg/50ml, 900mg/50ml
By Application
Hospital, Clinics, Recovery Center
By Companies
Pfizer, Akorn, Almaject, Baxter, Sagent, Sandoz, Fresenius Kabi, Alvogen, Fangming Pharmaceutical Group, Sinopharm, CSPC, Chendu Tiantaishan Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
204
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Clindamycin Phosphate Injection Market Report Segments:
The global Clindamycin Phosphate Injection market is segmented on the basis of:
Types
150mg/ml, 300mg/50ml, 600mg/50ml, 900mg/50ml
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinics, Recovery Center
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Akorn
- Almaject
- Baxter
- Sagent
- Sandoz
- Fresenius Kabi
- Alvogen
- Fangming Pharmaceutical Group
- Sinopharm
- CSPC
- Chendu Tiantaishan Pharma
Highlights of The Clindamycin Phosphate Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 150mg/ml
- 300mg/50ml
- 600mg/50ml
- 900mg/50ml
- By Application:
- Hospital
- Clinics
- Recovery Center
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Clindamycin Phosphate Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Clindamycin phosphate injection is a medication used to treat bacterial infections. It works by killing the bacteria that is causing the infection.
Some of the major companies in the clindamycin phosphate injection market are Pfizer, Akorn, Almaject, Baxter, Sagent, Sandoz, Fresenius Kabi, Alvogen, Fangming Pharmaceutical Group, Sinopharm, CSPC, Chendu Tiantaishan Pharma.
The clindamycin phosphate injection market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Clindamycin Phosphate Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Clindamycin Phosphate Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Clindamycin Phosphate Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Clindamycin Phosphate Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Clindamycin Phosphate Injection Market Size & Forecast, 2020-2028
4.5.1 Clindamycin Phosphate Injection Market Size and Y-o-Y Growth
4.5.2 Clindamycin Phosphate Injection Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 150mg/ml
5.2.2 300mg/50ml
5.2.3 600mg/50ml
5.2.4 900mg/50ml
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinics
6.2.3 Recovery Center
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Clindamycin Phosphate Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Clindamycin Phosphate Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 150mg/ml
9.6.2 300mg/50ml
9.6.3 600mg/50ml
9.6.4 900mg/50ml
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinics
9.10.3 Recovery Center
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 150mg/ml
10.6.2 300mg/50ml
10.6.3 600mg/50ml
10.6.4 900mg/50ml
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinics
10.10.3 Recovery Center
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 150mg/ml
11.6.2 300mg/50ml
11.6.3 600mg/50ml
11.6.4 900mg/50ml
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinics
11.10.3 Recovery Center
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 150mg/ml
12.6.2 300mg/50ml
12.6.3 600mg/50ml
12.6.4 900mg/50ml
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinics
12.10.3 Recovery Center
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 150mg/ml
13.6.2 300mg/50ml
13.6.3 600mg/50ml
13.6.4 900mg/50ml
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinics
13.10.3 Recovery Center
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Clindamycin Phosphate Injection Market: Competitive Dashboard
14.2 Global Clindamycin Phosphate Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Akorn
14.3.3 Almaject
14.3.4 Baxter
14.3.5 Sagent
14.3.6 Sandoz
14.3.7 Fresenius Kabi
14.3.8 Alvogen
14.3.9 Fangming Pharmaceutical Group
14.3.10 Sinopharm
14.3.11 CSPC
14.3.12 Chendu Tiantaishan Pharma
